<DOC>
	<DOCNO>NCT01957878</DOCNO>
	<brief_summary>Human Papillomavirus ( HPV ) 16 HPV 18 ( two virus genotype target ProCervix vaccine ) common HPV genotype associate least 70 % squamous cell carcinomas 82 % adenocarcinoma cervix The strategy therapeutic vaccination ProCervix activate enhance patient 's cellular immune response HPV . The therapeutic vaccine use woman infect HPV 16 , HPV 18 , . The vaccine target HPV infect woman normal mild cervical cellular dyskaryosis detectable infection oncogenic potential . This double-blind , randomise , placebo-controlled , parallel group study assess efficacy ProCervix placebo ( concomitantly administer imiquimod cream ) . ProCervix deliver topical agent , imiquimod , apply injection site vaccine adjuvant . The population propose study represent otherwise healthy female population infect HPV 16 and/or HPV 18 . The safety tolerability therapeutic vaccine show ongoing Phase I study , propose population may theory derive benefit vaccine .</brief_summary>
	<brief_title>Phase II Study HPV Therapeutic Vaccine HPV Infected Women With Normal Cytology ASCUS/LSIL</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Papilloma</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>A subject eligible inclusion study follow criterion apply : 1 . Subject female age 25 50 year ( inclusive ) . 2 . Subject premenopausal . 3 . Subject must cervical HPV 16 and/or 18 infection confirm RTPCR 4 . Subject cervical cytological evaluation normal , ASCUS LSIL result baseline . 5 . Subject employ highly effective contraception month prior first vaccination agree employ highly effective contraception least 12 month first vaccination . . 6 . Subject general good health base medical history physical examination . 7 . Subject able communicate effectively study personnel consider reliable , willing , cooperative term compliance protocol requirement . 8 . Subject voluntarily give write informed consent participate study . 1 . Subject current acute chronic disease , infection HPV , would expect interfere plan evaluation response 2 . Subject vaginal atrophy without topical hormonal therapy systemic selective estrogen receptor modulators ( SERMs ) . 3 . Subject prior exposure HPV prophylactic vaccine subject participate past another vaccination clinical trial related infection HPV 4 . Current high grade lesion history untreated high grade cervical lesion ( either CIN2 CIN3 ) . 5 . Subject current history cancer cervix . 6 . Subject clinically significant ( CS ) gynaecological abnormality could interfere study evaluation , judgment Investigator ( e.g . prolapse , myoma , fibroid , hysterectomy ) . 7 . Subject laboratory abnormality Grade â‰¥ 2 , define use Toxicity Grading Scale Healthy Adult Adolescent Volunteers Enrolled Preventative Vaccine Clinical Trials , 8 . Subject receive live viral vaccine within 3 month non live vaccine within 2 week first study product administration . 9 . Subject primary secondary systemic immunosuppression 10 . Subject history severe allergy ( require hospital care ) history severe asthma 11 . Subject history malignant cancer , except follow adequately treat cancer : basal cell carcinoma , dermatological squamous cell carcinoma . 12 . Subject administer another investigational drug vaccine within 30 day prior screen visit participate study . 13 . Subject know hypersensitivity imiquimod . 14 . Subject history severe reaction drug vaccination . 15 . Subject medical condition clinical and/or biological consequence judge Investigator incompatible vaccination ( ) . 16 . Subject positive result human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) . 17 . Subject symptomatic vaginal genital infection 18 . Subject history currently active genital herpes disease . 19 . Subject pregnant breastfeeding . 20 . Subject positive serum human chorionic gonadotrophin ( HCG ) result enrolment .</criteria>
	<gender>Female</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>